- RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This study looks at a new medicine called emicizumab for people with Type 3 Von Willebrand Disease. It compares emicizumab to standard treatments to see if it's safe and helps prevent bleeding.
For: Von Willebrand Disease, Type 3United States · Belgium · Canada - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
This study is looking at a medicine called emicizumab for babies up to 12 months old with severe haemophilia A. It aims to see how well it works, if it's safe, and how the body handles it, to help prevent bleeding episodes.
For: Severe Hemophilia AUnited States · Australia · Austria - Recruiting
Treatment of Hemophilia A Patients With FVIII Inhibitors
This study looks at how doctors manage Haemophilia A in men who develop ‘inhibitors’ to their treatment. It observes different treatments, including a new medicine called emicizumab, to see how well they work and if they are safe over up to five years.
For: Hemophilia AUnited States · Germany - Active not recruitingPHASE4
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
This study looks at how a medicine called emicizumab affects the overall health, activity levels, and joints of people with moderate or severe haemophilia A. It's for those already receiving another treatment and planning to switch to emicizumab.
For: Severe Hemophilia A · Moderate Hemophilia AUnited States · Brazil · Canada